Familial Defective Apolipoprotein B Versus Familial Hypercholesterolemia: An Assessment of Risk

ABSTRACT

Patients with familial hypercholesterolemia (FH) or familial defective apolipoprotein B (FDB) have severely increased low-density lipoprotein (LDL)-cholesterol levels and increased risk for premature coronary artery disease (CAD). Previous data on FDB patients were collected in patients referred to lipid clinics and were therefore subject to referral bias. We assessed the clinical phenotype of FDB in a population free from selection on CAD to compare the atherosclerotic burden with that of heterozygous FH. The study population was actively recruited in a large-scale screening program for inherited hypercholesterolemia in which FH and FDB heterozygotes were diagnosed by standard molecular techniques. Patients with FH and FDB had significantly higher plasma total cholesterol and LDL-cholesterol levels compared with their unaffected relatives. As with previous findings in FH, in FDB 19% of the carriers and 17% of the noncarriers of apoB mutations would have been misdiagnosed by cholesterol measurement alone, taking the age- and sex-specific 95th percentile as the diagnostic criterion. In FH patients the CAD risk was 8.5 relative to unaffected family members, whereas FDB patients had a 2.7-fold higher risk of CAD than unaffected relatives. FDB patients, free from clinical selection bias, do show lower total and LDL-cholesterol levels and lower CAD risk compared with FH heterozygotes. However, FDB patients are still exposed to a substantially higher CAD risk compared with unaffected relatives.

Familial defective apoB - hypercholesterolemia - cardiovascular risk - genetic testing

REFERENCES

• 1 WHO Consultation Report .Familial Hypercholesterolemia (FH). Report of a WHO Consultation: WHO/HGN/CONS/98.7
• 2 Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity T L. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100.  J Biol Chem. 2001;  276 9214-9218
• 3 Fouchier S W, Defesche J C, Umans-Eckenhausen M AW, Kastelein J JP. The molecular basis of familial hypercholesterolemia in The Netherlands.  Hum Genet. 2001;  109 602-615
• 4 Sijbrands E J, Westendorp R G, Defesche J C, de Meier P H, Smelt A H, Kastelein J JP. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study.  BMJ. 2001;  322 1019-1023
• 5 Umans-Eckenhausen M AW, Sijbrands E JG, Kastelein J JP, Defesche J C. LDL-receptor gene mutations and cardiovascular risk in a large genetic cascade screening population.  Circulation. 2002;  106 3031-3036
• 6 Defesche J C, Pricker K L, Hayden M R, van der Ende B E, Kastelein J J. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia.  Arch Intern Med. 1993;  153 2349-2356
• 7 Pimstone S N, Defesche J C, Clee S M, Bakker H D, Hayden M R, Kastelein J JP. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia.  Arterioscler Thromb Vasc Biol. 1997;  17 826-833
• 8 Hansen P S, Defesche J C, Kastelein J JP et al.. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries.  Arterioscler Thromb Vasc Biol. 1997;  17 741-747
• 9 Gaffney D, Reid J M, Cameron I M et al.. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia.  Arterioscler Thromb Vasc Biol. 1995;  15 1025-1029
• 10 Kalina A, Csaszar A, Czeizel A E et al.. Frequency of the R3500Q mutation of the apolipoprotein B-100 gene in a sample screened clinically for familial hypercholesterolemia in Hungary.  Atherosclerosis. 2001;  154 247-251
• 11 Rauh G, Keller C, Kormann B et al.. Familial defective apolipoprotein B100: clinical characteristics of 54 cases.  Atherosclerosis. 1992;  92 233-241
• 12 Umans-Eckenhausen M AW, Defesche J C, Sijbrands E J, Scheerder R L, Kastelein J JP. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands.  Lancet. 2001;  357 165-168
• 13 Defesche J C. Familial hypercholesterolemia. In: Betteridge DJ, Dunitz M Lipids and Vascular Disease London; Martin Dunitz 2000: 65-76
• 14 Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
• 15 Khoo K L, van Acker P, Defesche J C et al.. Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia.  Clin Genet. 2000;  58 98-105
• 16 Lombardi P, Sijbrands E J, van de Giessen G K et al.. Mutations in the low-density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing.  J Lipid Res. 1995;  36 860-867
• 17 Altman D G, Bland J M. Diagnostic tests 3: receiver operating characteristic plots.  BMJ. 1994;  309 188
• 18 Tybjaerg-Hansen A, Humphries S E. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease.  Atherosclerosis. 1992;  96 91-107
• 19 Tybjaerg-Hansen A, Steffensen R, Meinerts H, Schnohr P, Nordestgaard B C. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease.  N Engl J Med. 1998;  338 1577-1584
• 20 Twisk J, Gillian-Daniel D L, Tebon A, Wang L, Barrett P H, Attie A D. The role of the LDL receptor in apolipoprotein B secretion.  J Clin Invest. 2000;  105 521-532
• 21 Stalenhoef A FH, Defesche J C, Kleinveld H A, Demacker P NM, Kastelein J JP. Decreased resistance against in vitro oxidation of low-density lipoproteins from patients with familial defective apolipoprotein B100.  Arterioscler Thromb. 1994;  14 489-493
• 22 Sijbrands E JG, Westendorp R GJ, Lombardi M P et al.. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolemia.  Atherosclerosis. 2000;  149 421-425